[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558769":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Takeda","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All Participants",null,"Participants with post-transplant CMV infection and\u002For disease who are refractory and\u002For resistant to one or more prior therapy (including ganciclovir, valganciclovir, foscarnet or cidofovir) will be treated with LIVTENCITY tablet as per treating physician's discretion in a routine clinical practice setting, according to the approved labelling and will be observed prospectively for up to a 20-week period.",[13],"Drug: LIVTENCITY",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","LIVTENCITY","LIVTENCITY tablet.",[9],[21],"Maribavir",[23],{"name":24,"affiliation":5,"role":25},"Study Director","STUDY_DIRECTOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Takeda Contact","CONTACT","+1-877-825-3327","medinfoUS@takeda.com",[33],{"facility":34,"status":35,"city":36,"state":10,"zip":37,"country":38,"countryCode":10,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"The Catholic University of Korea, Seoul ST. Mary's Hospital","RECRUITING","Seoul","06591","South Korea",{"type":40,"coordinates":41},"Point",[42,43],126.9784,37.566,{"lat":43,"lon":42},[46,49],{"name":47,"role":29,"phone":10,"phoneExt":10,"email":48},"Site Contact","cho.sy@catholic.ac.kr",{"name":50,"role":51,"phone":10,"phoneExt":10,"email":10},"Cho Seong-yeon","PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100558769","a-study-of-livtencity-maribavir-in-adults-with-cytomegalovirus-cmv-infection-after-transplantation-in-south-korea-100558769",false,"NCT06555432","A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea","Post-Marketing Surveillance (Usage Results Study) of LIVTENCITY Tablet (Maribavir) for the Approved Indications in South Korea","Inclusion Criteria:\n\n* Participants with post-transplant CMV infection and\u002For disease who are refractory and\u002For resistant to one or more prior therapy including ganciclovir, valganciclovir, cidofovir or foscarnet.\n* Participants with age greater than or equal to (\\>=) 19 years.\n* Initiate first treatment course with maribavir.\n* Voluntarily consent to participate in the study.\n\nExclusion Criteria:\n\n* Participants for whom LIVTENCITY Tablet (maribavir) is contraindicated as per product label.\n* Participants previously treated with maribavir in any study or as marketed drug.\n* Participants actively participating in other clinical trials of post-transplant CMV infection treatment or with other experimental treatments.","ALL","19 Years",{"count":64,"type":65},168,"ESTIMATED","OBSERVATIONAL","Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. LIVTENCITY (Maribavir) is a medicine approved for treating CMV infection in adults after transplant in South Korea.\n\nThe main aim of this study is to learn how safe and effective LIVTENCITY (Maribavir) is in treating adults with CMV infection after transplant in a routine clinical practice setting.\n\nDuring the study, a participant's data will be collected for about 5 months (20 weeks). The study does not have fixed visits to the hospital, but it is recommended to visit the study doctor approximately 6 times during study.",[69],"Cytomegalovirus (CMV)",[71],"Drug Therapy","2025-11-14",{"date":74,"type":75},"2025-11-18","ACTUAL",{"date":77,"type":75},"2024-11-14",{"date":79,"type":65},"2028-10-01",{"name":5,"class":6},1]